Next Article in Journal
Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation
Next Article in Special Issue
Women’s Health: Contemporary Management of MS in Pregnancy and Post-Partum
Previous Article in Journal
Cytotoxicity of Extracts from New Zealand Surf Clams Against Organ Cancer Cell Lines
Previous Article in Special Issue
Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview
Open AccessReview

Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives

Baylor College of Medicine, Maxine Mesigner Multiple Sclerosis Center, Houston, TX 77030, USA
Authors to whom correspondence should be addressed.
Biomedicines 2019, 7(2), 26;
Received: 25 January 2019 / Revised: 22 March 2019 / Accepted: 25 March 2019 / Published: 30 March 2019
(This article belongs to the Special Issue Multiple Sclerosis: Diagnosis and Treatment)
PDF [361 KB, uploaded 30 March 2019]


Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune disease of the central nervous system (CNS). Disease-modifying therapies (DMT) targeting inflammation have been shown to reduce disease activity in patients with relapsing–remitting MS (RRMS). The current therapeutic challenge is to find an effective treatment to halt disease progression and reverse established neural damage. Stem cell-based therapies have emerged to address this dilemma. Several types of stem cells have been considered for clinical use, such as autologous hematopoietic (aHSC), mesenchymal (MSC), neuronal (NSC), human embryonic (hESC), and induced pluripotent (iPSC) stem cells. There is convincing evidence that immunoablation followed by hematopoietic therapy (aHSCT) has a high efficacy for suppressing inflammatory MS activity and improving neurological disability in patients with RRMS. In addition, MSC therapy may be a safe and tolerable treatment, but its clinical value is still under evaluation. Various studies have shown early promising results with other cellular therapies for CNS repair and decreasing inflammation. In this review, we discuss the current knowledge and limitations of different stem cell-based therapies for the treatment of patients with MS. View Full-Text
Keywords: multiple sclerosis; stem cells; autologous hematopoietic; mesenchymal; neuronal; induced pluripotent; human embryonic multiple sclerosis; stem cells; autologous hematopoietic; mesenchymal; neuronal; induced pluripotent; human embryonic

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Cuascut, F.X.; Hutton, G.J. Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives. Biomedicines 2019, 7, 26.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top